InMed Pharmaceuticals News | Press Releases

Skip to content

Facebook Twitter Linkedin

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Menu

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Press Releases

InMed Pharmaceuticals Signs Agreement with the National Research Council of Canada for Cannabinoid Biofermentation Process Development and Scale-Up

October 3, 2018

InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids

September 25, 2018

InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2018 Financial Results and Provides R&D and Business Update

September 13, 2018

InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work

September 11, 2018

InMed Files Patent Application for its Cannabinoid Biosynthesis Program

September 10, 2018

InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2018 Financial Results and Business Update on September 13, 2018

September 7, 2018

InMed Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference

August 31, 2018

InMed to Present at the Canaccord Genuity 38th Annual Growth Conference

August 1, 2018

InMed Pharmaceuticals Announces the Closing of C$14.95 Million Bought Deal Financing including Full Exercise of Underwriter’s Over-Allotment Option

June 21, 2018

InMed to Present at the 8th Annual LD Micro Invitational Conference

May 29, 2018

InMed Files Patent Application for INM-085 Glaucoma Program

May 14, 2018

InMed Reports Third Quarter Fiscal 2018 Financial Results and Business Updates

May 11, 2018

InMed Appoints Dr. Vikramaditya G. Yadav to Scientific Advisory Board

May 1, 2018

InMed Rings the Opening Bell at the Toronto Stock Exchange

April 17, 2018

InMed Announces Appointment of Joshua Blacher as Chief Business Officer

April 11, 2018

InMed Pharmaceuticals Announces Graduation to Toronto Stock Exchange

March 23, 2018

InMed Appoints Dr. Eric Hsu as Vice President, Preclinical Research and Development

March 13, 2018

InMed to Present at 30th Annual ROTH Capital Conference

March 12, 2018

InMed Announces Peer-Reviewed Publication in Drug Delivery and Translational Research

March 6, 2018

InMed Receives Conditional Approval to List on the Toronto Stock Exchange

March 2, 2018

« Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Next »

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.

#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

Cannabinoids in Development
INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
Neurodegenerative Disease
Novel Cannabinoid Analogs

MANUFACTURING

Cannabinoid Manufacturing Expertise
IntegraSyn™ Cannabinoid Manufacturing
BayMedica Cannabinoid Biosynthesis
Rare Cannabinoid Ingredients

Investor

News
Events
Stock Information
Corporate Governance
Financials & AGM
Filings
Presentations
Media

CORPORATE

Management
Board of Directors
Scientific Advisory Board
Partners and Collaborators
Careers
Contact

Learn

What is Cannabinol (CBN)?
What is Epidermolysis Bullosa (EB)?
What is Glaucoma?
Cannabinoid Manufacturing Economics 101
GMP Manufacturing Standards by Product Type
Cannabinoids for Glaucoma
Cannabinoid Science
Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

Privacy Policy
Terms of Use
Legal Disclaimer

Find Us On:

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*

First name* Last name*

Email*

Consent

By providing your e-mail address, you consent to receive news, press releases, quarterly and annual reports, presentations and other information from InMed Pharmaceuticals Inc. You can unsubscribe at any time.